Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?
H Guo, M Lu, Y Ma, X Liu - International Journal of Neuroscience, 2021 - Taylor & Francis
H Guo, M Lu, Y Ma, X Liu
International Journal of Neuroscience, 2021•Taylor & FrancisObjectives There is a primary muscular affection in spinal and bulbar muscular atrophy
(SBMA). Myoglobin (Myo) is mainly distributed in the myocardium and skeletal muscle. The
purpose of the study was to explore the significance of serum Myo detection in the diagnosis
and clinical evaluation of SBMA. Materials and methods In this study, serum creatine kinase
(CK), Myo, and Troponin T (cTNT) levels were assessed in 80 patients with SBMA and were
compared with those of 60 patients with amyotrophic lateral sclerosis (ALS). All …
(SBMA). Myoglobin (Myo) is mainly distributed in the myocardium and skeletal muscle. The
purpose of the study was to explore the significance of serum Myo detection in the diagnosis
and clinical evaluation of SBMA. Materials and methods In this study, serum creatine kinase
(CK), Myo, and Troponin T (cTNT) levels were assessed in 80 patients with SBMA and were
compared with those of 60 patients with amyotrophic lateral sclerosis (ALS). All …
Objectives
There is a primary muscular affection in spinal and bulbar muscular atrophy (SBMA). Myoglobin (Myo) is mainly distributed in the myocardium and skeletal muscle. The purpose of the study was to explore the significance of serum Myo detection in the diagnosis and clinical evaluation of SBMA.
Materials and methods
In this study, serum creatine kinase (CK), Myo, and Troponin T (cTNT) levels were assessed in 80 patients with SBMA and were compared with those of 60 patients with amyotrophic lateral sclerosis (ALS). All measurement data were analyzed using the t-test and enumeration data using the χ2-test.
Results
The rate of abnormal Myo levels in the SBMA group was 100%, however, none of the patients with ALS had an abnormal Myo level. There was no overlap between the two groups. The Myo levels in patients with SBMA were correlated with the course of the disease. Further, their CK level was significantly elevated compared with that in patients with ALS, however, there was an overlap between the two groups. The serum cTNT level in patients with SBMA was not significantly different from that in patients with ALS.
Conclusion
Myo, as a simple, inexpensive, and readily available biochemical indicator, is likely to be used for the differentiation between SBMA and ALS, and used as a new biomarker for the clinical evaluation of SBMA.
Taylor & Francis Online